硅谷銀行-2024年健康技術(shù)的未來 The Future of Healthtech 2024_第1頁
硅谷銀行-2024年健康技術(shù)的未來 The Future of Healthtech 2024_第2頁
硅谷銀行-2024年健康技術(shù)的未來 The Future of Healthtech 2024_第3頁
硅谷銀行-2024年健康技術(shù)的未來 The Future of Healthtech 2024_第4頁
硅谷銀行-2024年健康技術(shù)的未來 The Future of Healthtech 2024_第5頁
已閱讀5頁,還剩7頁未讀, 繼續(xù)免費(fèi)閱讀

下載本文檔

版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡介

ReportPreview

ReachouttoyourSVBpointofcontacttogainaccesstothefullversionofthereport.

October2024

ReportPreview

TurningaNewcorner

WelcometoourFutureofHealthtech2024report,acomprehensiveanalysisofchallenges,trendsandopportunitiesintoday’shealthtechinnovationmarket.

Weenteredthisyearwithcautiousoptimism,whichstillringstrueinthethirdquarter.Therearereasonstobeconcerned.Slowerinvestmentpacesand

smallerchecksizesmarkthecurrentinvestmentenvironment.Investorshaveheightenedexpectationsaroundstronguniteconomics,scalabilityandpathstoprofitability.

Normalizationinvaluationsisinfullforce,withvaluationsacrossallstagesunderscrutiny.Atleast12%ofreporteddealsaredownrounds,markingthehighestlevelinthesector’shistory(page9).Therearearecordnumberof

unlabeledandunpricedextensionrounds,wherecompaniesareleaningonexistinginvestorstodelayoravoidavalueadjustment,hopingmarketforces,techinnovationorinvestorconfidencewillletthemgrowintotheir

valuationsbeforetheirrunwayvanishes.However,companiesthatare

strugglingtoraisetheseinsideroundsarehavingtolookatM&A,costcuttinganddownroundsastheircoffersempty,suggestingthe“markdownhammer”hasyettodropfully(page10).

Still,weareinamarkedlydifferentplacethanwewerein2023,andwemaybeturningacorner.Interestrateshavefinallybeguntolower,inflationhascooledslightlyandpublicmarketsremainvolatilebutaregettingstronger.

Thesemacroeconomicimprovementshaveprovidedamuch-neededboosttothespace.Thesharpdropsininvestmenthavetapered,withinvestment

showingsignsofearlyrecovery.Quarterlyinvestmentoverthelastthree

quartersconsistentlyhoveredbetween$4.0Band$4.5B—markedlyhigher

thantheaveragequarterlyinvestmentin2019($3.0B).Early-stagedealactivity

hasgrowntorecordheights(page7),surpassingeven2021levels.

Artificialintelligence(AI)andmachine-learning(ML)techarebringingnew

enthusiasmintothesector,withAIsolutionsachievingstunningtractionandrevenueramprates.Thetransformationisfeltmostinthehealthcareback

office.Virtualassistantsandrevenuecyclemanagementtoolshavetakentheleadininvestmentonthestrengthofclearerrevenuepropositionsandeasierdeployments(page17).Value-basedcare(VBC)hascontinuedtoevolve,as

specialtycarestartupscreatenew,moreintegratedmodelsofcarethatuseAI

foressentialdataanalysisandoutreach(page14).

Despitethesector’stumultuousfewyears,healthtechstartupscontinueto

produceamazinginnovation,frombringingtherighthealthcaretotheright

patientattherighttimetofindingincreasinglybetterwaystosupportprovidersandletthemfocusontheircoremission:helpingpatients.Startupsthatcan

meetthoseneeds,providingmeasurable,provableresultstotheircustomers,

areleadingthehealthtechindustrybacktowardsunnydays.

JulieBettsEbert

ManagingDirector

LifeScience&HealthcareBanking

jbetts@

svb》SBiaiinckonvaiieySource:PitchBookData,Inc.,SVBproprietarydataandSVBanalysis.

ADivisionofFirstcitizensBankTHEFUTUREOFHEALTHTECH2024|2

ADivisionofFirstcitizensBank

THEFUTUREOFHEALTHTECH2024|3

ReportPreview

Fourthemesemergingaboutthefutureofhealthtech

Buildinganewnormal

Growthisslow,but2021isstillweighingthemarketdown.

There’snoendinsightfortheongoing

valuationadjustmentsthroughdownroundsanddealterms.Thatsaid,

investmentamountsandvolumenumbersareshowingappetite

amonginvestorstorebuildandreevaluateportfolios.

Therearemorecompaniesholding

on,hopingnottoneedadownround.Weexpecttoseemorevaluationsfallbutoverallinvestmenttokeeprising.

pleaseexitthroughanywhereatall

Exitsaregettinghardertofindacrosstheboard.

Bigwinnersfrompreviousyears

arenowstrugglingwithinflated

valuationsanddifficultexitpaths.DespitesomesuccessfulrecentIPOs,overallpublichealthtech

performancestilllookspoor.

WithM&Aslowing,investorswillneedtobewillingtogobackto10-or15-

yearhorizonsforhealthtech.

AdministrativeAlisleadingthecharge

ClinicalAIisinthebackseatfornow.

Inthefaceofgrowinguncertaintyabouttheeffectivenessandvalueofclinical

healthAI,administrativeandback-officesolutionsaredrivinginvestmentand

activityinhealthtechAI.

AshealthcarerecoversfromthelastAIhypecycles,clearROIandquantifiableperformancearethemostimportant

factorsinAIdeployments.HealthcareprovidersseemtobecomfortablewithwhereandhowtodeployadministrativeAI.Theydon’tseemtofeelthatway

aboutclinicalAIyet.

valuemmbasedcare

needsintegratedcare

Specialistsaretheboomingfrontierofvalue-basedcare.

There’sagrowingrecognitionthat

coordinationandcollaborationbetweenprimarycareproviders(PCPs)and

specialistsisessentialtomeetingthegoalsofVBCcontracts.

Techthatcanhelpsolvetheproblems

ofdataexchange,patientattributionandcarecoordinationhasavitalroletoplayinthisgrowingecosystem.

svb》SBiaiinckonvaley

ADivisionofFirstcitizensBank

THEFUTUREOFHEALTHTECH2024|4

ReportPreview

TheFutureofHealthtech2024report

Togetthefullreport,reachouttoyourSVBpointofcontact

What’sinside:

svb》SBiaiinckonvaley

ReportPreview

LeadAuthors

JulieBettsEbert

ManagingDirectorLifeScience&

HealthcareBanking

jbetts@

JulieBettsEbertisaManagingDirectoronthe

NationalLifeScience&Healthcareteamat

SiliconValleyBank,coveringtheMid-AtlanticandSoutheastmarkets.Julieprovidesspecialized

bankingservicesanddebt-financingsolutionsandadviceonstrategicgrowthtolifesciencecompaniesacrossallsectorsandlifestages.

JuliereceivedanMBAwithhonorsfromColumbia

BusinessSchoolandaB.S.fromtheMcIntireSchoolofCommerceattheUniversity

ofVirginiawithaconcentrationinfinance.

JackieSpencer

HeadofRelationship

ManagementforLifeScience&HealthcareBanking

jspencer@

JackieSpencerleadstheUSRelationshipManagementteamforLifeScienceand

HealthcareAcceleratorandGrowth.Jackieandherteamarefocusedonprovidingbankingandfinancingsolutionstoinnovativecompaniesinthissector.

SincejoiningSVBin2007,Jackiehasworkedacrossboththetechnologyandhealthcarepracticesfromemergingmarkettolate-stagecorporatefinance.

JackiegraduatedfromSaintMary’sCollegeof

Californiawithhonors,receivingabachelor’sinfinance.

NinaKandilian

SeniorVicePresident

HealthcareVentureCapitalRelationshipManagement

nkandilian@

NinaKandilianmanagesrelationshipswithtraditionalVCfirmsfocusedonhealthcareandlifescience

investments.PriortoSVB,sheledproductmarketingandstrategyatvarioushealthtechstartups

andwaspartofthefoundingteamattheMassChallengeHealthtechstartupacceleratorprogram.NinastartedhercareerattheMassGeneralBrighamhealthsystemin

variousproductanddigitaltransformationroles.

NinareceivedherMBAatBabsonCollegeandabachelor’sdegreefromSuffolkUniversity.

contributors

RaysaBousleiman

VicePresident

HealthcareVentureCapitalRelationshipManagement

rbousleiman@

DennisHe

ManagingDirectorLifeSciences

dhe@

NuziBarkatally

VicePresident

LifeScience&HealthcareStartupBanking

nbarkatally@

BillSideris

Director

LifeScienceandHealthcare

bsideris@

MarketInsightsTeamAuthors

TimotLamarre

Researcher

MarketInsights

tlamarre@

AlexanderLennox-Miller

SeniorResearcherMarketInsights

alennoxmille@

ReportAcknowledgments

Thankyoutothefollowingforlendingtheirsubject-matterexpertisetothisreport:

polarispartnersal6z

svb》SBiaiinckonvaley

5

ADivisionofFirstcitizensBankAllnon-SVBnamedcompaniesareindependentthirdpartiesandarenotaffiliatedwithSiliconValleyBank,adivisionofFirst-CitizensBank&TrustCompany.

ReportPreview

Disclaimers

TheviewsexpressedinthisreportaresolelythoseoftheauthorsanddonotnecessarilyreflecttheviewsofSVB.

Thismaterial,includingwithoutlimitationtothestatisticalinformationherein,isprovidedforinformationalpurposesonly.Thematerialisbasedinpartoninformationfromthird-partysourcesthatwebelievetobereliablebutwhichhasnotbeenindependentlyverifiedbyus,and,assuch,wedonotrepresenttheinformationis

accurateorcomplete.Theinformationshouldnotbeviewedastax,accounting,investment,legalorotheradvice,norisittobereliedoninmakinganinvestmentorotherdecision.Youshouldobtainrelevantandspecificprofessionaladvicebeforemakinganyinvestmentdecision.Nothingrelatingtothematerialshouldbe

construedasasolicitation,offerorrecommendationtoacquireordisposeofanyinvestment,ortoengageinanyothertransaction.

Allnon-SVBnamedcompanieslistedthroughoutthisdocument,asrepresentedwiththevariousstatistical,thoughts,analysisandinsi

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲(chǔ)空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。

最新文檔

評(píng)論

0/150

提交評(píng)論